{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039953","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.198570+00:00","generated_at":"2026-06-08T09:49:01.147730+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Intelligent Bio Solutions Q1 FY2024 revenue up 191% to $0.91M; net loss widens to $2.4M","bullets":["Revenue + government support income of $0.91M vs $0 in year-ago quarter; sales of goods $0.8M from IFP acquisition.","Net loss attributable to INBS of $2.4M vs $1.2M; driven by IFP combined results offset by $131,250 fair value gain.","Cash and equivalents $0.2M as of Sep 30; raised ~$4.378M ($3.35M net) in October 2023 public offering.","Expanded into New Zealand and South America (TSCOM SPA distribution deal); added eight new Australian customers.","Completed development milestone for ketamine and tramadol assays; ISO 13485:2016 recertified."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039953","json":"https://secwatch.observer/filing/0001493152-23-039953.json","markdown":"https://secwatch.observer/filing/0001493152-23-039953.md","text":"https://secwatch.observer/filing/0001493152-23-039953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223039953/0001493152-23-039953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223039953/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:49:01.147730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57173154f9cf0e5c89c97b6ade232b722eeb3a73","claim":"INTELLIGENT BIO SOLUTIONS INC. reported fiscal first quarter ended September 30, 2023 results: revenue combined revenue and government support income increased by 191% to $0.91 million, net income Net loss attributable to INBS for the first fiscal quarter ended September 30, 2023 was $2.4 million.","evidence_excerpt":"The Company’s combined revenue and government support income increased by 191% to $0.91 million for the first fiscal quarter ended September 30, 2023, including revenue from sales of goods of $0.8 million, compared to $0 in the first fiscal quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725430/000149315223039953/0001493152-23-039953-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal first quarter ended September 30, 2023"},{"label":"Revenue","value":"combined revenue and government support income increased by 191% to $0.91 million"},{"label":"Net income","value":"Net loss attributable to INBS for the first fiscal quarter ended September 30, 2023 was $2.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}